This analysis demonstrated that expression levels of MMP1 and MMP12 were increased in patients with residual tumors post-treatment, whereas RAF1 expression was higher in patients who were tumor-free post-treatment (Supplementary Figure S1). The gene discussed is RAF1; the disease is neoplasm.